ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock, including 2,426,470 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $17.00 per share. The gross proceeds from the offering to ACADIA, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA, are approximately $316.2 million. BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC acted as the joint book-running managers for the offering. Cowen and Company, LLC act
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness Wire
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at HC Wainwright from $33.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
ACAD
Earnings
- 5/8/24 - Beat
ACAD
Sec Filings
- 5/9/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/3/24 - Form 4
- ACAD's page on the SEC website